OOIR: Observatory of International Research

Papers

(The H4-Index of JNCI-Journal of the National Cancer Institute is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Correction to: ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications	231
Vertical integration in oncology: what does it mean for patients with cancer?	183
Re: Deng and Heybati	136
Response to Liu and Zhang	131
Factors associated with timely COVID-19 vaccination in a population-based cohort of patients with cancer	105
Evaluating a blood test for colon cancer screening: how simulation modeling can inform clinical policy making and research	98
Addressing Diversity, Equity, and Inclusion at the JNCI Journals	87
Pre- and post-diagnostic use of antihypertensive medications and stage I-III colorectal cancer survival: prospective cohort study	86
Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Cancer Active Lifestyle Study	79
Independent associations between obesity, glucose metabolism, and breast cancer risk through unrelated pathways	73
Discovering plasma proteins associated with breast cancer incidence in postmenopausal women in the Atherosclerosis Risk in Communities study	72
Mediators of Racial Disparities in Heart Dose Among Whole Breast Radiotherapy Patients	71
RE: Exploring the cross-cancer effect of circulating proteins and discovering potential intervention targets for 13 site-specific cancers	70
Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination	68
Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020	66
The National Cancer Policy Forum: a strong voice for improving cancer care and outcomes	62
The impact of HIV on cervical cancer elimination in KwaZulu-Natal: a comparative modeling analysis	61
Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer	60
Dyslipidemia and cardiovascular disease among childhood cancer survivors: a St. Jude Lifetime Cohort report	60
Joint associations of accelerometer-measured physical activity and cardiovascular-kidney-metabolic syndrome stages with the risks of cancer and all-cause mortality	59
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment	56
Method of primary breast cancer detection and the disease-free interval, adjusting for lead time	54
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial	54
Understanding risk factors for endometrial cancer in young women	50
RE: Use of artificial intelligence for cancer clinical trial enrollment	50

Rare cancers research: current state of knowledge and emerging opportunities for prevention and interception	49
Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study	49
Ethylene oxide emissions and incident breast cancer and non-Hodgkin lymphoma in a US cohort	48
Long-term aspirin use and cancer risk: a 20-year cohort study	48
Survivorship after adolescent and young adult cancer: models of care, disparities, and opportunities	48
RE: Prevalence of cancer survivors in the United States	47
Cancer prevention in context: interplay of perceived discrimination, neighborhood deprivation, and cancer-related risk and protective factors	47
Health-related quality of life by race, ethnicity, and country of origin among cancer survivors	47
Impact of knowledge of human papillomavirus positivity on cervical cytology performance in Latin America	46
RE: Autoimmune disease and the risk of anal cancer in the US elderly population	46
Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study	45
Leisure-time physical activity after diagnosis and survival by cancer type: a pooled analysis	44
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line col	44
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer	42
Cancer control co-benefits of the climate-related provisions in the American Inflation Reduction Act	42
Redefining rurality: adopting an identity-based and community-engaged approach to defining rural cancer disparities	41
Correction to: Obesity-Specific Improvement of Lung Cancer Outcomes and Immunotherapy Efficacy with Metformin	41